Compare KKR & Co Inc (KKR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Pfizer Inc — how do they compare? KKR & Co Inc trades at $90.95 (market cap $80.39B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Pfizer Inc for 158 Days on average.
| KKR | PFE | |
|---|---|---|
Market Cap | $80.39B | $158.56B |
Volume | 6,517,705 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $142.75 | $29.02 |
52-Week Low | $83.88 | $23.67 |
Typical Hold Time | 67 Days | 158 Days |
Enterprise Value | $2.95B | $210.06B |
Dividend Yield | 0.87% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $89.56, down 0.12% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. Recent earnings show a mixed track record, with Q2 2026 beating estimates but Q4 2025 missing. The company maintains strong analyst support with a consensus price target of $123.30 and 24 buy ratings. Recent news highlights active deal-making, including a joint venture with Thomson Reuters and investments in AI infrastructure, signaling ongoing strategic expansion.
The outlook for KKR is positive based on robust analyst sentiment and strategic investments, but risks include volatile cash flows and high debt levels. Investors may find opportunity in the significant upside to the price target, though macroeconomic sensitivity and execution risks warrant caution.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
